Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Vision blurred, Vomiting, Weight decreased
Clinical narrative: Lost 20 LBS  (After Second Shot); Fever (Unknown Fahrenheit)  (After Second Shot); Chills  (After Second Shot); Very Sick (After Second Shot); Lost Voice  (After Second Shot); Massive Headaches  (After Second Shot); Numbness in the Face  (After Second Shot); Nausea  (After Second Shot); Vomiting  (After Second Shot); Diarrhea  (After Second Shot); Blurred Vision  (After Second Shot); Very Unhappy  (After Second Shot); She has not been able to work (After Second Shot); This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Very Sick (After Second Shot)), APHONIA (Lost Voice  (After Second Shot)), HEADACHE (Massive Headaches  (After Second Shot)), HYPOAESTHESIA (Numbness in the Face  (After Second Shot)), NAUSEA (Nausea  (After Second Shot)), VOMITING (Vomiting  (After Second Shot)), DIARRHOEA (Diarrhea  (After Second Shot)), VISION BLURRED (Blurred Vision  (After Second Shot)), DEPRESSED MOOD (Very Unhappy  (After Second Shot)), IMPAIRED WORK ABILITY (She has not been able to work (After Second Shot)), WEIGHT DECREASED (Lost 20 LBS  (After Second Shot)), PYREXIA (Fever (Unknown Fahrenheit)  (After Second Shot)) and CHILLS (Chills  (After Second Shot)) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 064A21A) for COVID-19 vaccination.     The patient's past medical history included Headache. Concurrent medical conditions included Stress and Chronic migraine.   On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-May-2021, the patient experienced ILLNESS (Very Sick (After Second Shot)) (seriousness criterion hospitalization), APHONIA (Lost Voice  (After Second Shot)) (seriousness criterion hospitalization), HEADACHE (Massive Headaches  (After Second Shot)) (seriousness criterion hospitalization), HYPOAESTHESIA (Numbness in the Face  (After Second Shot)) (seriousness criterion hospitalization), NAUSEA (Nausea  (After Second Shot)) (seriousness criterion hospitalization), VOMITING (Vomiting  (After Second Shot)) (seriousness criterion hospitalization), DIARRHOEA (Diarrhea  (After Second Shot)) (seriousness criterion hospitalization), VISION BLURRED (Blurred Vision  (After Second Shot)) (seriousness criterion hospitalization), DEPRESSED MOOD (Very Unhappy  (After Second Shot)) (seriousness criterion hospitalization) and IMPAIRED WORK ABILITY (She has not been able to work (After Second Shot)) (seriousness criterion disability). On 04-Jul-2021, the patient experienced WEIGHT DECREASED (Lost 20 LBS  (After Second Shot)) (seriousness criterion hospitalization prolonged), PYREXIA (Fever (Unknown Fahrenheit)  (After Second Shot)) (seriousness criterion hospitalization) and CHILLS (Chills  (After Second Shot)) (seriousness criterion hospitalization). The patient was hospitalized on 04-Jul-2021 due to APHONIA, CHILLS, DEPRESSED MOOD, DIARRHOEA, HEADACHE, HYPOAESTHESIA, ILLNESS, NAUSEA, PYREXIA, VISION BLURRED, VOMITING and WEIGHT DECREASED. The patient was treated with SUMATRIPTAN SUCCINATE (IMITREX DF) at an unspecified dose and frequency and CHLORPROMAZINE (THORAZINE [CHLORPROMAZINE]) at an unspecified dose and frequency. At the time of the report, ILLNESS (Very Sick (After Second Shot)), APHONIA (Lost Voice  (After Second Shot)), HEADACHE (Massive Headaches  (After Second Shot)), HYPOAESTHESIA (Numbness in the Face  (After Second Shot)), NAUSEA (Nausea  (After Second Shot)), VOMITING (Vomiting  (After Second Shot)), DIARRHOEA (Diarrhea  (After Second Shot)), VISION BLURRED (Blurred Vision  (After Second Shot)), DEPRESSED MOOD (Very Unhappy  (After Second Shot)), IMPAIRED WORK ABILITY (She has not been able to work (After Second Shot)), WEIGHT DECREASED (Lost 20 LBS  (After Second Shot)), PYREXIA (Fever (Unknown Fahrenheit)  (After Second Shot)) and CHILLS (Chills  (After Second Shot)) outcome was unknown.            No concomitant medications were reported.  Treatment medications also included Steroid IV. Company comment: Very limited information regarding these events has been provided at this time. Further information has been requested.; Sender's Comments: Very limited information regarding these events has been provided at this time. Further information has been requested.